|
**Overview**: DNA Profiling Transplantation Panel**Introduction**: The DNA Profiling Transplantation Panel is a diagnostic tool designed to establish transplant compatibility using whole blood samples. In India, allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplants (kidney, liver) are increasing (~10,000â€"15,000 HSCT and ~10,000 kidney transplants annually), with accurate donor-recipient DNA profiling essential to prevent rejection, graft-versus-host disease, or chimerism misinterpretation. High morbidity from under-testing in rural/low-SES transplant candidates, limited molecular labs, delayed matching leading to graft failure or relapse. Per molecular pathology practices aligned with ICMR, Indian Society of Blood and Marrow Transplantation, and Indian Society of Organ Transplantation guidelines, the test employs PCR for donor/recipient DNA profiles over 1-2 days with high accuracy, valuable for pre-transplant compatibility and post-transplant chimerism baseline. This diagnostic falls under transplant screening and targets donor-recipient pairs before HSCT or organ transplant, addressing accurate detection to guide HLA typing confirmation and immunosuppression planning. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise matching, facilitating successful transplants, and reducing rejection burden. Its whole blood-based approach ensures reliable DNA profiling in India's expanding transplant programs.**Other Names**: DNA Transplant Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: STR-based profiling standard; in India, essential in transplant registries.**Purpose**: The test assesses 2 parameters including donor DNA profile to guide transplant compatibility evaluation, establish baseline, inform matching.**Test Parameters**: 1. Donor DNA Profile, 2. Recipient DNA Profile.**Pretest Condition**: No fasting required; patients should be pre-transplant donor-recipient pairs.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on transplant type, donor relationship, prior transfusions, HLA typing.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of incompatible transplant including rejection, benefits of accurate profiling, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Distinct donor/recipient profiles confirm compatibility baseline, necessitating specialist input.**Specialist Consultation**: Transplant hematologists or surgeons should be consulted for interpretation.**Additional Supporting Tests**: HLA typing, cross-match for confirmation.**Test Limitations**: Pre-transplant only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Transplant Studies India 2023. |
